Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dade Behring goes public

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics firm completes pre-packaged Chapter 11 debt restructuring and enters the public market with a new board of directors Oct. 3. The firm expects to complete Nasdaq registration within six months; common equity initially will be traded over-the-counter, with prices listed in the pink sheets. In August, Dade Behring announced a debt-to-equity swap to cover $1.5 bil. in liabilities for the company, then privately held (1"The Gray Sheet" Aug. 5, 2002, p. 16)...

You may also be interested in...



Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003

Dade Behring's focus on growing its clinical lab diagnostics business while reducing debt, combined with a rising profile on Wall Street and plans to enter the high-volume testing category, are buoying the firm's stock price

Dade’s New Dimension: In Hospital Cost-Cutting Environment, Size Matters

Dade Behring anticipates launching a next-generation Dimension integrated chemistry analyzer system in "high-volume" laboratories in 2005, targeting a $5 bil. worldwide market

Dade Behring To Restructure $1.5 Bil. Debt, Become Public Firm

Diagnostics manufacturer Dade Behring hopes to emerge from its Aug. 1 Chapter 11 bankruptcy protection filing as a public company by October

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel